Amita Aggarwal1, Ramnath Misra. 1. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 226 014. amita@sgpgi.ac.in
Abstract
OBJECTIVES: Methotrexate (MTX) is one of the most widely used disease-modifying antirheumatoid drugs in the treatment of juvenile rheumatoid arthritis (JRA). We studied its effect on the production of two proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha), by peripheral blood cells in patients with JRA. METHODS: Interleukin-6 and TNFalpha levels were measured at 0 and 4 weeks in whole blood cultures with and without lipopolysaccharide (LPS) stimulation in 19 children treated with MTX (10 mg/m(2 )per week) or placebo. Ten healthy individuals were included as healthy controls. RESULTS: Spontaneous production of IL-6 and TNFalpha by peripheral blood cells of patients with JRA was higher than in healthy controls ( P<0.01). However, IL-6 and TNFalpha production after LPS stimulation was similar in healthy controls and patients. The two groups of patients, i.e., those treated with placebo and those treated with MTX, had similar spontaneous and induced IL-6 and TNFalpha production. At 4 weeks, the drop in spontaneous IL-6 and TNFalpha production was no different in the two groups, but LPS-stimulated IL-6 production was significantly lower in the MTX-treated group than the placebo group ( P<0.05). CONCLUSION: Methotrexate reduces the production of IL-6 by activated cells, and this may be responsible for its anti-inflammatory property.
OBJECTIVES:Methotrexate (MTX) is one of the most widely used disease-modifying antirheumatoid drugs in the treatment of juvenile rheumatoid arthritis (JRA). We studied its effect on the production of two proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha), by peripheral blood cells in patients with JRA. METHODS:Interleukin-6 and TNFalpha levels were measured at 0 and 4 weeks in whole blood cultures with and without lipopolysaccharide (LPS) stimulation in 19 children treated with MTX (10 mg/m(2 )per week) or placebo. Ten healthy individuals were included as healthy controls. RESULTS: Spontaneous production of IL-6 and TNFalpha by peripheral blood cells of patients with JRA was higher than in healthy controls ( P<0.01). However, IL-6 and TNFalpha production after LPS stimulation was similar in healthy controls and patients. The two groups of patients, i.e., those treated with placebo and those treated with MTX, had similar spontaneous and induced IL-6 and TNFalpha production. At 4 weeks, the drop in spontaneous IL-6 and TNFalpha production was no different in the two groups, but LPS-stimulated IL-6 production was significantly lower in the MTX-treated group than the placebo group ( P<0.05). CONCLUSION:Methotrexate reduces the production of IL-6 by activated cells, and this may be responsible for its anti-inflammatory property.
Authors: K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath Journal: Clin Exp Immunol Date: 1999-10 Impact factor: 4.330
Authors: J T Cassidy; J E Levinson; J C Bass; J Baum; E J Brewer; C W Fink; V Hanson; J C Jacobs; A T Masi; J G Schaller Journal: Arthritis Rheum Date: 1986-02
Authors: T C Wascher; J Hermann; R Brezinschek; H P Brezinschek; M Wilders-Truschnig; F Rainer; G J Krejs Journal: Eur J Clin Invest Date: 1994-01 Impact factor: 4.686
Authors: P Barrera; A M Boerbooms; E M Janssen; R W Sauerwein; H Gallati; J Mulder; T de Boo; P N Demacker; L B van de Putte; J W van der Meer Journal: Arthritis Rheum Date: 1993-08
Authors: Samuel A Jacobs; Nicholas Vidnovic; Hitendra Patel; Lorinda A Soma; Yuan Chang; Noah Bass; Steven H Swerdlow Journal: Clin Rheumatol Date: 2006-07-06 Impact factor: 3.650
Authors: Chen-Ting Lee; Kathleen M Kokolus; Nicholas D Leigh; Maegan Capitano; Bonnie L Hylander; Elizabeth A Repasky Journal: PLoS One Date: 2015-03-20 Impact factor: 3.240
Authors: Karina I Halilova; Elizabeth E Brown; Sarah L Morgan; S Louis Bridges; Min-Ho Hwang; Donna K Arnett; Maria I Danila Journal: Int J Rheumatol Date: 2012-07-09
Authors: Carl K Edwards; Julie S Green; Hans-Dieter Volk; Michael Schiff; Brian L Kotzin; Hiroaki Mitsuya; Tatsuya Kawaguchi; Ken-Mei Sakata; John Cheronis; David Trollinger; Danute Bankaitis-Davis; Charles A Dinarello; David A Norris; Michael P Bevilacqua; Mayumi Fujita; Gerd-Rudiger Burmester Journal: Front Immunol Date: 2012-12-04 Impact factor: 7.561